|
1
|
Brandner JM, Haftek M and Niessen CM:
Adherens junctions, desmosomes and tight junctions in epidermal
barrier function. Open Dermatol J. 4:14–20. 2010. View Article : Google Scholar
|
|
2
|
Green KJ, Getsios S, Troyanovsky S and
Godsel LM: Intercellular junction assembly, dynamics, and
homeostasis. Cold Spring Harb Perspect Biol. 2:a0001252010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Niessen CM: Tight junctions/adherens
junctions: Basic structure and function. J Invest Dermatol.
127:2525–2532. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneeberger EE and Lynch RD: The tight
junction: A multifunctional complex. Am J Physiol Cell Physiol.
286:C1213–C1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shin K, Fogg VC and Margolis B: Tight
junctions and cell polarity. Annu. Rev. Cell Dev. Biol. 22:207–235.
2006.
|
|
6
|
Oliveira SS and Morgado-Díaz JA: Claudins:
Multifunctional players in epithelial tight junctions and their
role in cancer. Cell Mol Life Sci. 64:17–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin TA and Jiang WG: Loss of tight
junction barrier function and its role in cancer metastasis.
Biochim Biophys Acta. 1788:872–891. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Van Itallie CM and Anderson JM: The
molecular physiology of tight junction pores. Physiology
(Bethesda). 19:331–338. 2004.PubMed/NCBI
|
|
9
|
Saitou M, Furuse M, Sasaki H, Schulzke JD,
Fromm M, Takano H, Noda T and Tsukita S: Complex phenotype of mice
lacking occludin, a component of tight junction strands. Mol Biol
Cell. 11:4131–4142. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Günzel D and Yu AS: Claudins and the
modulation of tight junction permeability. Physiol Rev. 93:525–569.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hadj-Rabia S, Baala L, Vabres P,
Hamel-Teillac D, Jacquemin E, Fabre M, Lyonnet S, De Prost Y,
Munnich A, Hadchouel M and Smahi A: Claudin-1 gene mutations in
neonatal sclerosing cholangitis associated with ichthyosis: A tight
junction disease. Gastroenterology. 127:1386–1390. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morin PJ: Claudin proteins in human
cancer: Promising new targets for diagnosis and therapy. Cancer
Res. 65:9603–9606. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Morita K, Furuse M, Fujimoto K and Tsukita
S: Claudin multigene family encoding four-transmembrane domain
protein components of tight junction strands. Proc Natl Acad Sci
USA. 96:511–516. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
González-Mariscal L, Tapia R and Chamorro
D: Crosstalk of tight junction components with signaling pathways.
Biochim Biophys Acta. 1778:729–756. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Itoh M, Furuse M, Morita K, Kubota K,
Saitou M and Tsukita S: Direct binding of three tight
junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH
termini of claudins. J Cell Biol. 147:1351–1363. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Swisshelm K, Macek R and Kubbies M: Role
of claudins in tumorigenesis. Adv Drug Deliv Rev. 57:919–928. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miwa N, Furuse M, Tsukita S, Niikawa N,
Nakamura Y and Furukawa Y: Involvement of claudin-1 in the
beta-catenin/Tcf signaling pathway and its frequent upregulation in
human colorectal cancers. Oncol Res. 12:469–476. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Angelow S, Ahlstrom R and Yu AS: Biology
of claudins. Am J Physiol Renal Physiol. 295:F867–F876. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krause G, Winkler L, Mueller SL, Haseloff
RF, Piontek J and Blasig IE: Structure and function of claudins.
Biochim Biophys Acta. 1778:631–645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Günzel D and Fromm M: Claudins and other
tight junction proteins. Compr Physiol. 2:1819–1852.
2012.PubMed/NCBI
|
|
21
|
Osanai M, Takasawa A, Murata M and Sawada
N: Claudins in cancer: Bench to bedside. Pflugers Arch. 469:55–67.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tabariès S and Siegel PM: The role of
claudins in cancer metastasis. Oncogene. 36:1176–1190. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Escudero-Esparza A, Jiang WG and Martin
TA: The Claudin family and its role in cancer and metastasis. Front
Biosci (Landmark Ed). 16:1069–1083. 2010. View Article : Google Scholar
|
|
24
|
Lal-Nag M and Morin PJ: The claudins.
Genome Biol. 10:2352009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ouban A and Ahmed AA: Claudins in human
cancer: A review. Histol Histopathol. 25:83–90. 2010.PubMed/NCBI
|
|
26
|
Morohashi S, Kusumi T, Sato F, Odagiri H,
Chiba H, Yoshihara S, Hakamada K, Sasaki M and Kijima H: Decreased
expression of claudin-1 correlates with recurrence status in breast
cancer. Int J Mol Med. 20:139–143. 2007.PubMed/NCBI
|
|
27
|
Kinugasa T, Huo Q, Higashi D, Shibaguchi
H, Kuroki M, Tanaka T, Futami K, Yamashita Y, Hachimine K, Maekawa
S, et al: Selective up-regulation of claudin-1 and claudin-2 in
colorectal cancer. Anticancer Res. 27:3729–3734. 2007.PubMed/NCBI
|
|
28
|
Tabariès S, Dong Z, Annis MG, Omeroglu A,
Pepin F, Ouellet V, Russo C, Hassanain M, Metrakos P, Diaz Z, et
al: Claudin-2 is selectively enriched in and promotes the formation
of breast cancer liver metastases through engagement of integrin
complexes. Oncogene. 30:1318–1328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jääskeläinen A, Soini Y, Jukkola-Vuorinen
A, Auvinen P, Haapasaari KM and Karihtala P: High-level cytoplasmic
claudin 3 expression is an independent predictor of poor survival
in triple-negative breast cancer. BMC Cancer. 18:2232018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang L, Wang Y, Zhang B, Zhang H, Zhou M,
Wei M, Dong Q, Xu Y, Wang Z, Gao L, et al: Claudin-3 expression
increases the malignant potential of lung adenocarcinoma cells:
Role of epidermal growth factor receptor activation. Oncotarget.
8:23033–23047. 2017.PubMed/NCBI
|
|
31
|
Agarwal R, D'Souza T and Morin PJ:
Claudin-3 and claudin-4 expression in ovarian epithelial cells
enhances invasion and is associated with increased matrix
metalloproteinase-2 activity. Cancer Res. 65:7378–7385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rangel LB, Agarwal R, D'Souza T, Pizer ES,
Alò PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR and Morin PJ:
Tight junction proteins claudin-3 and claudin-4 are frequently
overexpressed in ovarian cancer but not in ovarian cystadenomas.
Clin Cancer Res. 9:2567–2575. 2003.PubMed/NCBI
|
|
33
|
Blackwell KE, Calcaterra TC and Fu YS:
Laryngeal dysplasia: Epidemiology and treatment outcome. Ann Otol
Rhinol Laryngol. 104:596–602. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jiang L, Yang YD, Fu L, Xu W, Liu D, Liang
Q, Zhang X, Xu L, Guan XY, Wu B, et al: CLDN3 inhibits cancer
aggressiveness via Wnt-EMT signaling and is a potential prognostic
biomarker for hepatocellular carcinoma. Oncotarget. 5:7663–7676.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gao M, Li W, Wang H and Wang G: The
distinct expression patterns of claudin-10, −14, −17 and E-cadherin
between adjacent non-neoplastic tissues and gastric cancer tissues.
Diagn Pathol. 8:2052013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Berx G, Becker KF, Höfler H and van Roy F:
Mutations of the human E-cadherin (CDH1) gene. Hum Mutat.
12:226–237. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Christofori G and Semb H: The role of the
cell-adhesion molecule E-cadherin as a tumour-suppressor gene.
Trends Biochem Sci. 24:73–76. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Berx G and Van Roy F: The
E-cadherin/catenin complex: An important gatekeeper in breast
cancer tumorigenesis and malignant progression. Breast Cancer Res.
3:289–293. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hirohashi S: Inactivation of the
E-cadherin-mediated cell adhesion system in human cancers. Am J
Pathol. 153:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kwon MJ: Emerging roles of claudins in
human cancer. Int J Mol Sci. 14:18148–18180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Turksen K and Troy TC: Junctions gone bad:
Claudins and loss of the barrier in cancer. Biochim Biophys Acta.
1816:73–79. 2011.PubMed/NCBI
|
|
44
|
Furuse M, Hata M, Furuse K, Yoshida Y,
Haratake A, Sugitani Y, Noda T, Kubo A and Tsukita S: Claudin-based
tight junctions are crucial for the mammalian epidermal barrier a
lesson from claudin-1-deficient mice. J Cell Biol. 156:1099–1111.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Singh AB, Sharma A and Dhawan P: Claudin
family of proteins and cancer: An overview. J Oncol.
2010:5419572010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Findley MK and Koval M: Regulation and
roles for claudin-family tight junction proteins. IUBMB Life.
61:431–437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hewitt KJ, Agarwal R and Morin PJ: The
claudin gene family: Expression in normal and neoplastic tissues.
BMC Cancer. 6:1862006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kominsky SL: Claudins: Emerging targets
for cancer therapy. Expert Rev Mol Med. 8:1–11. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Michl P, Barth C, Buchholz M, Lerch MM,
Rolke M, Holzmann KH, Menke A, Fensterer H, Giehl K, Löhr M, et al:
Claudin-4 expression decreases invasiveness and metastatic
potential of pancreatic cancer. Cancer Res. 63:6265–6271.
2003.PubMed/NCBI
|
|
50
|
Chang TL, Ito K, Ko TK, Liu Q,
Salto-Tellez M, Yeoh KG, Fukamachi H and Ito Y: Claudin-1 has tumor
suppressive activity and is a direct target of RUNX3 in gastric
epithelial cells. Gastroenterology. 138:255–265. e1-3. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kaufhold S and Bonavida B: Central role of
Snail1 in the regulation of EMT and resistance in cancer: A target
for therapeutic intervention. J Exp Clin Cancer Res. 33:622014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bhat AA, Pope JL, Smith JJ, Ahmad R, Chen
X, Washington MK, Beauchamp RD, Singh AB and Dhawan P: Claudin-7
expression induces mesenchymal to epithelial transformation (MET)
to inhibit colon tumorigenesis. Oncogene. 34:4570–4580. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lu Z, Ding L, Hong H, Hoggard J, Lu Q and
Chen YH: Claudin-7 inhibits human lung cancer cell migration and
invasion through ERK/MAPK signaling pathway. Exp Cell Res.
317:1935–1946. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Balda MS, Garrett MD and Matter K: The
ZO-1-associated Y-box factor ZONAB regulates epithelial cell
proliferation and cell density. J Cell Biol. 160:423–432. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hamazaki Y, Itoh M, Sasaki H, Furuse M and
Tsukita S: Multi-PDZ domain protein 1 (MUPP1) is concentrated at
tight junctions through its possible interaction with claudin-1 and
junctional adhesion molecule. J Biol Chem. 277:455–461. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Bose CK and Mukhopadhyay A: Claudin and
ovarian cancer. J Turk Ger Gynecol Assoc. 11:48–54. 2010.PubMed/NCBI
|
|
59
|
Ouban A: Claudin-1 role in colon cancer:
An update and a review. Histol Histopathol. 33:1013–1019.
2018.PubMed/NCBI
|
|
60
|
Cheung ST, Leung KL, Ip YC, Chen X, Fong
DY, Ng IO, Fan ST and So S: Claudin-10 expression level is
associated with recurrence of primary hepatocellular carcinoma.
Clin Cancer Res. 11:551–556. 2005.PubMed/NCBI
|
